Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00216567 |
Recruitment Status :
Completed
First Posted : September 22, 2005
Last Update Posted : February 1, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Epilepsy, Rolandic | Drug: topamax | Phase 4 |
Benign rolandic epilepsy (BRE) is a common seizure disorder confined solely to children. The disorder is marked clinically by nocturnal generalized tonic-clonic seizures and diurnal seizures consisting of simple partial seizures consisting of brief unilateral facial clonic activity, dysphasia, and drooling. The EEG abnormalities are unique, consisting of generally high amplitude, centrotemporal spikes that are activated by sleep. The seizures typically begin in the first decade and almost always stop by age 16 years. The seizures are usually infrequent although clusters of seizures do occur. When the physician elects to treat, the seizures are usually easily controlled. This is a randomized, open label, active controlled, multi-center based clinical trial to determine the efficacy and safety of Topiramate comparing with Carbamazepine in Benign rolandic epilepsy. The study hypothesis is that topiramate will be more effective in treatment of Benign rolandic epilepsy than Carbamazepine, as evaluated by seizure-free rate at 24 weeks and Intellectual Functioning : KEDI-WISC (Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised) and is generally well-tolerated.
Topiramate (target dose) 4mg/kg/day, B.I.D, oral, for 24 weeks, carbamazepine(target dose) 30mg/kg/day, B.I.D, oral, for 24 weeks.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 114 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy. |
Study Start Date : | December 2002 |
Actual Study Completion Date : | February 2006 |

- Seizure-free rate at 24 weeks in comparison of topiramate to carbamazepine
- In comparison of topiramate to carbamazepine, Intellectual Functioning : KEDI-WISC (Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 15 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects whose guardians submitted written consent
- Subjects with more than 2 seizures in last 1 year
- Subjects showing one of the following additional criteria
- Psychological burden due to seizure
- Seizure in daytime
- More than 3 seizures in last 6 month
- Convulsive seizure
Exclusion Criteria:
- Abnormalities on MRI, EEG
- Mental retardation
- History of seizure relapse
- Seizures due to organic causes
- Medically serious acute or chronic disease or progressive and degenerative disorders
- Patients who have received an investigational medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00216567
Study Director: | Janssen Korea, Ltd. Clinical Trial | Janssen Korea, Ltd. |
ClinicalTrials.gov Identifier: | NCT00216567 |
Other Study ID Numbers: |
CR005077 |
First Posted: | September 22, 2005 Key Record Dates |
Last Update Posted: | February 1, 2011 |
Last Verified: | January 2011 |
Benign rolandic epilepsy Topiramate |
Epilepsy Epilepsy, Rolandic Brain Diseases Central Nervous System Diseases Nervous System Diseases Epilepsies, Partial |
Epileptic Syndromes Topiramate Anticonvulsants Hypoglycemic Agents Physiological Effects of Drugs |